<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208063</url>
  </required_header>
  <id_info>
    <org_study_id>0112</org_study_id>
    <nct_id>NCT02208063</nct_id>
  </id_info>
  <brief_title>A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma Antibiotics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus
      standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin
      (PCN), or cefazolin) in the treatment of subjects with complicated Staphylococcus aureus (S.
      aureus) bacteremia and SA right-sided infective endocarditis (RIE).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Anticipated">April 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response (success or failure)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>Clinical response (success or failure) for subjects with uncomplicated bacteremia receiving 2 to 4 weeks of treatment at test of cure (TOC) (38 [+/-2] days after randomization), for subjects with complicated bacteremia receiving 4 to 6 weeks of treatment at test of cure (TOC) (52 [+/-2] days after randomization), and for subjects with endocarditis receiving 6 weeks of treatment at test of cure (TOC) (52 [+/-2] days after randomization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of new metastatic foci of infection</measure>
    <time_frame>After Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of bacteremia</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>For subjects with a positive S. aureus blood culture on Day 1, time to all blood cultures negative for S. aureus for two days in succession</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Telavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin, Daptomycin, synthetic penicillin or Cefazolin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telavancin</intervention_name>
    <arm_group_label>Telavancin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synthetic penicillin</intervention_name>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Nafcillin</other_name>
    <other_name>Oxacillin</other_name>
    <other_name>Cloxacillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older with at least one blood culture positive for S. aureus within
             48 hours before randomization

          -  At least one of the following signs or symptoms of bacteremia:

               -  Temperature ≥ 38.0°C

               -  WBC count &gt; 10,000 or &lt; 4,000 cells/µL or &gt; 10% immature neutrophils (bands)

               -  Tachycardia (heart rate &gt; 90 bpm)

               -  Tachypnea (respiratory rate &gt; 20 breaths/min)

               -  Hypotension (systolic blood pressure &lt; 90 mmHg)

               -  Signs or symptoms of localized catheter-related infection

          -  At enrollment, subjects must have either 1) known right-sided infective endocarditis
             by Modified Duke's criteria 2) known complicated bacteremia, demonstrated as signs or
             symptoms of metastatic foci of S. aureus infection or 3) at least one risk factor for
             complicated bacteremia.

        Exclusion Criteria:

          -  Treatment with any potentially effective (anti-staphylococcal) systemic antibiotic for
             more than 60 hours within 7 days before randomization. EXCEPTION: Documented
             resistance to the prior systemic antibacterial therapy

          -  Presence of an infection source that will not be managed or controlled within the
             first 3 days of study drug treatment

          -  Presence of prosthetic cardiac valve or cardiac device (eg, implantable cardioverter
             defibrillator [ICD]), permanent pacemaker, or cardiac valve support ring)

          -  Known or suspected left-sided infective endocarditis (LIE), by Modified Duke Criteria.
             NOTE: Right-sided infective endocarditis (RIE) is permitted

          -  Known or suspected osteomyelitis or meningitis. NOTE: Evidence of metastatic
             complications related to the primary infection such as right-sided endocarditis,
             septic arthritis, septic pulmonary emboli are permitted. S. aureus pneumonia is
             permitted

          -  Confirmed evidence (identification or gram stain) of a mixed polymicrobial infection
             with a Gram-negative pathogen that requires non-study antibiotic treatment with
             agent(s) that have activity against Gram-negative pathogens
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bibiana Castaneda, MD</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma R &amp; D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Remington-Davis Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2014</study_first_submitted>
  <study_first_submitted_qc>August 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2014</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bacteremia</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Telavancin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

